Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash from Financing Activities (2022 - 2025)

Oramed Pharmaceuticals' Cash from Financing Activities history spans 4 years, with the latest figure at $46.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed N/A year-over-year to $46.1 million; the TTM value through Dec 2025 reached -$4.7 million, changed N/A, while the annual FY2025 figure was -$4.7 million, 90.89% up from the prior year.
  • Cash from Financing Activities reached $46.1 million in Q4 2025 per ORMP's latest filing, up from -$1.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $74.5 million in Q3 2023 to a low of -$30.6 million in Q2 2024.
  • Average Cash from Financing Activities over 4 years is $5.3 million, with a median of $2.3 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: soared 1628.45% in 2023, then crashed 881.89% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $4.2 million in 2022, then crashed by 698.8% to -$25.0 million in 2023, then soared by 94.84% to -$1.3 million in 2024, then soared by 3670.88% to $46.1 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cash from Financing Activities are $46.1 million (Q4 2025), -$1.3 million (Q3 2024), and -$30.6 million (Q2 2024).